# US 2015/0105464 A1 · 4-oxo-2-pentenoic acid and brain health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105464 A1
- Document ID: US20150105464A1
- Status: Published application
- Kind: A1
- Application number: 14/389,082
- Filed: 2013-03-25
- Published: 2015-04-16
- Earliest claimed: 2012-03-30
- Assignees: Nestec S.A.
- Applicants: Nestec S.A.
- Inventors: Francia Jacqueline Arce Vera; Bertrand Bourqui; Timo Buetler; Stephane Duboux; Jane Durga; Francis Foata; Philippe Alexandre Guy; Nicolas Page; Serge Andre Dominique Rezzi; Pierre Magistretti; Evelyne Ruchti; Sylvain Lengacher; Igor Allaman
- Web page: https://patentgrep.com/patent/US20150105464A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 1/20: Bacteria; Culture media therefor
- C12P 7/40: containing a carboxyl group {including Peroxycarboxylic acids}
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/519: Breve
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cognitive decline.

## Claims

### Claim 1

A method for the treatment or prevention of cognitive decline comprising administering a non-pharmaceutical composition comprising 4-oxo-2-pentenoic acid to an individual having or at risk of cognitive decline.

### Claim 2 (depends on 1)

Method in accordance with claim 1, for use in the treatment or prevention of memory loss.

### Claim 3 (depends on 1)

Method in accordance with claim 1 for the treatment or prevention of loss of learning capability.

### Claim 4 (depends on 1)

Method in accordance with claim 1, wherein the 4-oxo-2-pentenoic acid is obtained from natural sources.

### Claim 5 (depends on 1)

Method in accordance with claim 1, wherein the 4-oxo-2-pentenoic acid is obtainable from Bifidobacterium breve CNCM I-3865 or Bifidobacterium breve ATCC 15700.

### Claim 6 (depends on 5)

Method in accordance with claim 5, wherein the Bifidobacterium breve CNCM I-3865 or Bifidobacterium breve ATCC 15700 was heat treated at about 60-180° C.

### Claim 7 (depends on 1)

Method in accordance with claim 1, wherein the composition comprises 4-oxo-2-pentenoic acid in an amount of at least 1 mg per kg of the composition.

### Claim 8 (depends on 1)

Method in accordance with claim 1, wherein the composition is administered in a daily dose corresponding to between 2 μg and 20 mg of 4-oxo-2-pentenoic acid per kg of body weight.

### Claim 9 (depends on 1)

Method in accordance with claim 1, wherein the composition is administered orally or enterally.

### Claim 10 (depends on 1)

Method in accordance with claim 1, wherein the composition is administered to humans or pets.

### Claim 11 (depends on 1)

Method in accordance with claim 1, wherein the composition is administered to adults.

### Claim 12 (depends on 1)

Method in accordance with claim 1, wherein the composition is selected from the group consisting of a food composition, a food additive, a nutraceutical, a drink, a nutritional formulation, a tube feeding formulation, a powdered composition to be reconstituted in milk or water, and a pet food composition.
